Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 16;51(2):115-130.

Brexanolone to Treat Postpartum Depression in Adult Women

Elyse M Cornett  1 , Lauren Rando  1 , Austin M Labbé  1 , Wil Perkins  1 , Adam M Kaye  1 , Alan David Kaye  1 , Omar Viswanath  1 , Ivan Urits  1
Affiliations
Review

Brexanolone to Treat Postpartum Depression in Adult Women

Elyse M Cornett et al. Psychopharmacol Bull. .

Abstract

ZULRESSO (Brexanolone) is a novel FDA-approved treatment for moderate-to-severe postpartum depression. Postpartum depression may be diagnosed in women experiencing depressive symptoms which can manifest as cognitive, behavioral, or emotional disturbances as early as the third trimester to 4 weeks following delivery. The efficacy of brexanolone suggests that neurosteroids such as allopregnanolone are important to treat PPD. However, it is currently unclear if brexanolone provides lasting relief of depressive symptoms at or beyond 30 days following administration. Further studies are necessary to make this determination.

Keywords: GABA; ZULRESSO; brexanolone; major depressive disorder; postpartum depression.

PubMed Disclaimer

References

    1. Dacarett-Galeano DJ, Diao XY. Brexanolone: a novel therapeutic in the treatment of postpartum depression. Am J Psychiatry Resid J. 2019;15(2):2–4.
    1. Walton N, Maguire J. Allopregnanolone-based treatments for postpartum depression: why/how do they work. Neurobiol Stress. 2019;11:100198. - PMC - PubMed
    1. Powell JG, Garland S, Preston K, Piszczatoski C. Brexanolone (Zulresso): finally, an FDA-approved treatment for postpartum depression. Ann Pharmacother. 2020;54(2):157–163. - PubMed
    1. The Medical Letter on Drugs and Therapeutics. 2019
    1. Frieder A, Fersh M, Hainline R, Deligiannidis KM, Professor of Psychiatry A, Zucker B. Pharmacotherapy of Postpartum Depression. Current Approaches and Novel Drug Development. HHS Public Access. - PMC - PubMed